Melatonin 3 mg for Sleep Disorder
This trial is testing whether N-of-1 methods can be used to study the effects of melatonin on sleep quality. Participants will be given a Fitbit and 3 bottles of pills, one with melatonin, one with a lower dose of melatonin, and one with a placebo. They will take the pills for 2 weeks, then not take them for 2 weeks, and repeat this 6 times. At the end, they will answer some surveys about the experience.
- Sleep Disorder
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a site
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
How many participants are being recruited for this research?
"Affirmative. Based on the data presented by clinicaltrials.gov, this medical research project was initially launched on May 11th 2022 and is actively seeking 60 volunteers from 1 clinic site."
What potential negative impacts could Melatonin 3 mg have on human health?
"Our team at Power determined that Melatonin 3 mg is relatively low risk, and so assigned it a score of 1. This assessment was based on the fact that this medication has only undertaken Phase 1 clinical trials; limited data exists concerning its safety and efficacy."
Are there any opportunities for involvement in this medical trial at present?
"Clinicaltrials.gov details that participants are being sought for this medical study; its first posting was on May 11th 2022 and it's been updated as recently as July 7th 2022."
What are the fundamental aims of this clinical exploration?
"The primary outcome being assessed in this clinical trial is the Mean System Usability Score (SUS). Secondary measurements include changes to sleep quality, participant adherence to placebo supplement intake and Fitbit-recorded sleep duration. The latter two values will be calculated as proportions of days adherent across all participants with respective means and standard deviations provided. Changes to sleep quality over time are evaluated via Generalized Linear Mixed Model analyses while within-participant differences in Fitbit device recorded sleep duration are evaluated similarly. Assessments take place 14 weeks after baseline results have been reported back to the patient."